NBTX

Nanobiotix S.A. Form 6-K Summary (Period Ended June 30, 2024)

Business Context and Reporting Period

This Form 6-K incorporates Nanobiotix S.A.'s Half-Year Financial Report for the six-month period ended June 30, 2024. Nanobiotix is a late-stage clinical biotechnology company focused on nanophysics-based therapeutic approaches, primarily advancing its lead product candidate, NBTXR3, a radioenhancer for cancer treatment. The company operates under a global licensing agreement with Janssen Pharmaceutica NV (Johnson & Johnson) for the co-development and commercialization of NBTXR3.

Key Financial Metrics

Revenue Composition: Revenue of €6.2 million was driven by the Janssen Agreement, including €2.7 million in services (license assignment and R&D), €1.1 million in technology transfer, and €2.4 million in product supply. Other income included a €2.3 million research tax credit.

Material Changes vs. Prior Period

• Revenue Recognition: The company recognized €6.2 million in revenue in H1 2024 compared to zero in H1 2023, primarily due to the Janssen Agreement. This included a €20 million milestone payment received in Q2 2024 for achieving operational requirements in the NANORAY-312 Phase 3 trial.
• Net Loss Improvement: Net loss decreased by €6.2 million (22% reduction) year-over-year, driven by revenue recognition and a favorable financial result (€1.9 million gain vs. €2.7 million loss in 2023), partially offset by increased R&D expenses.
• Operating Expenses: R&D expenses increased by €4.2 million (23%) to €22.0 million, reflecting increased clinical development activities for the NANORAY-312 trial and hiring of a Chief Medical Officer. SG&A expenses remained stable at €10.8 million.
• Liquidity: Cash and cash equivalents increased significantly to €66.3 million from €21.6 million in the prior year period, bolstered by the Janssen milestone payment and short-term bank deposits.

Guidance, Outlook, and Risks

Outlook and Milestones:

• NANORAY-312 Trial: Global sponsorship of the pivotal Phase 3 head and neck cancer trial (NANORAY-312) is being transferred to Janssen. The interim analysis is now expected to be reported after the last patient is recruited in the first half of 2026.
• NSCLC Development: The FDA issued a "Study May Proceed" letter for a Phase 2 study in non-small-cell lung cancer (NSCLC) sponsored by Janssen.
• Study 1100 Data: Positive data presented at ASCO 2024 showed an overall response rate of 48% in anti-PD-1 naïve patients with recurrent/metastatic head and neck cancer treated with NBTXR3 followed by anti-PD-1.

Risks and Contingencies:

• Reliance on Janssen: The company faces risks related to its dependence on Janssen for co-development and commercialization, including potential disagreements or termination of the agreement.
• Liquidity: While management estimates sufficient liquidity for the next 12 months, the company has a history of operating losses and will require additional funding (equity, debt, or milestones) to sustain operations long-term.
• Regulatory and Clinical: Risks include delays in clinical trials, failure to meet regulatory requirements, and the uncertainty of commercialization success.

Key Facts for Investor Verification

• Milestone Payment: Verify the receipt and accounting treatment of the $20 million (€18.1 million) milestone payment from Janssen received in Q2 2024.
• Cash Runway: Confirm the €66.3 million cash balance and the company's projection of sufficient liquidity for at least 12 months.
• Debt Structure: Review the EIB loan terms, which include royalty-based interest indexed to future NBTXR3 sales, totaling approximately €36.9 million in liability as of June 30, 2024.
• Trial Timeline: Monitor the transfer of sponsorship for the NANORAY-312 trial to Janssen and the revised timeline for interim data readout (H1 2026).
• Revenue Recognition: Understand the allocation of the Janssen transaction price between upfront payments, milestones, and future R&D services under IFRS 15.